Urine NT-proBNP Concentration Detection Kit Based on Aptamer-Mediated CRISPR / Cas12a Signal Transduction

By utilizing the aptamer-mediated CRISPR/Cas12a signal conversion mechanism, the device dependence and insufficient sensitivity issues in urine NT-proBNP concentration detection have been resolved, enabling non-invasive and convenient urine NT-proBNP concentration detection, suitable for non-laboratory scenarios.

CN122836336BActive Publication Date: 2026-11-17NINGBO FIRST HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611318718.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-08-28
Publication Date
2026-11-17
Estimated Expiration
2046-08-28

AI Technical Summary

Technical Problem

Existing NT-proBNP concentration detection technologies rely on blood samples and large-scale equipment, making them difficult to apply to urine samples and non-laboratory scenarios, especially in terms of sensitivity and rapid detection.

Method used

The study employed an aptamer-mediated CRISPR/Cas12a signal transduction mechanism, utilizing the binding of a specific aptamer to NT-proBNP to alter the activity of the Cas12a-crRNA complex. The concentration of NT-proBNP in urine was quantitatively detected by assessing the degree of cleavage by a dual-labeled DNA reporter probe, and the results were analyzed in conjunction with the colorimetric results from lateral chromatography test strips.

Benefits of technology

It enables the detection of NT-proBNP concentration in urine without the need for large equipment, with high sensitivity and simple operation. It is suitable for non-laboratory scenarios, home monitoring and community screening, and reduces testing costs and complexity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122836336B_ABST
    Figure CN122836336B_ABST
Patent Text Reader

Abstract

This invention discloses a urine NT-proBNP concentration detection kit based on aptamer-mediated CRISPR / Cas12a signal transduction, belonging to the field of biodetection technology. The kit includes a specific aptamer, CRISPR reaction components, a dual-labeled DNA reporter probe, reaction buffer, and a lateral chromatography test strip. The specific aptamer has an NT-proBNP binding region and a Cas12a activation region. The CRISPR reaction components include Cas12a protein, crRNA, and an RNase inhibitor; the crRNA contains a guide sequence that recognizes the Cas12a activation region. The dual-labeled DNA reporter probe is labeled with FAM and Biotin at both ends, respectively. This invention requires no blood samples, large equipment, or specialized operation, and is suitable for urine samples and non-laboratory scenarios, meeting the needs of point-of-care testing in home monitoring, community healthcare, and rapid triage in emergency departments.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of NT-proBNP concentration detection technology, and in particular relates to a urine NT-proBNP concentration detection kit based on aptamer-mediated CRISPR / Cas12a signal transduction. Background Technology

[0002] Heart failure is a clinical syndrome associated with abnormalities in cardiac structure or function, and its development is accompanied by changes in myocardial wall tension and volume overload. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the biologically inactive N-terminal fragment formed after the cleavage of pro-B-type natriuretic peptide. Its concentration changes are correlated with cardiac workload and have been used as an adjunct to the assessment and monitoring of heart failure. Therefore, accurate, sensitive, and rapid detection of NT-proBNP concentration in biological samples has significant clinical application value.

[0003] Currently, NT-proBNP concentration is primarily determined using immunological detection methods, such as chemiluminescence immunoassay, electrochemiluminescence immunoassay, enzyme-linked immunosorbent assay (ELISA), and immunochromatographic assay. These methods typically use whole blood, serum, or plasma as the sample. Some of these methods rely on large analytical equipment, specialized reagents, and skilled personnel, and blood sample collection is somewhat invasive, limiting their application in home monitoring, community screening, and point-of-care rapid testing. Existing commercially available in vitro diagnostic reagents for NT-proBNP concentration are also primarily applicable to whole blood, serum, or plasma. No publicly available product information explicitly lists urine as an applicable sample for clinical in vitro quantitative detection in commercially available kits.

[0004] Urine samples are convenient, non-invasive, and easy to repeat. NT-proBNP does not bind to natriuretic peptide receptors and is not easily degraded via neutral endopeptidase-mediated pathways; the kidneys are its important clearance organ. In their article "Diagnostic and prognostic value of urine NT-proBNP levels in heart failure patients," published in the *European Journal of Heart Failure*, Vol. 8, No. 6, 2006, pp. 621-627, Ng et al. (LL Ng, IA Loke, RJ O'Brien, et al.) demonstrated the feasibility of using urine as a sample for NT-proBNP detection by measuring urinary NT-proBNP levels in heart failure patients and controls. However, converting this method into a test kit suitable for non-laboratory settings still faces the following technical obstacles: (1) The composition of urine is complex, and the differences in ions and endogenous substances between different urine samples may interfere with the specific recognition and signal conversion of NT-proBNP; (2) The concentration of NT-proBNP in urine is usually low, requiring high detection sensitivity. However, existing commercial reagents that use blood samples are difficult to use directly for the detection of NT-proBNP in urine. (3) Traditional immunoassay methods rely on antibodies, enzyme-linked immunosorbent assay (ELISA) readers or chemiluminescence devices, which are difficult to meet the rapid detection needs in non-laboratory environments.

[0005] Therefore, how to convert the binding events of low concentrations of NT-proBNP in urine to recognition molecules into readable and quantifiable detection signals without relying on large-scale equipment is a technical problem that urgently needs to be solved in this field. Summary of the Invention

[0006] The technical problem to be solved by this invention is: addressing the issue that existing NT-proBNP concentration immunoassay technologies rely on blood samples, large equipment, and specialized operations, making them difficult to apply to urine samples and non-laboratory scenarios, this invention provides a urine NT-proBNP concentration detection kit based on aptamer-mediated CRISPR / Cas12a signal transduction.

[0007] The technical solution adopted by this invention to solve the above-mentioned technical problems is: a urine NT-proBNP concentration detection kit based on aptamer-mediated CRISPR / Cas12a signal conversion, comprising: The specific aptamer has two functional regions: an NT-proBNP binding region, which specifically binds to NT-proBNP; and a Cas12a activation region, which is recognized by crRNA. When the specific aptamer is in a free state, its Cas12a activation region can be recognized by crRNA, thereby activating the trans-cleavage activity of the Cas12a-crRNA complex. When the specific aptamer binds to NT-proBNP to form an aptamer-NT-proBNP complex, its Cas12a activation region cannot be recognized by crRNA due to steric hindrance or conformational changes, thus failing to activate the Cas12a-crRNA complex. Based on the above mechanism, the total amount of the specific aptamer added is excessive relative to the amount of NT-proBNP corresponding to the detection limit of the kit; the detection limit refers to the highest concentration of NT-proBNP in urine that the kit can accurately quantify. The CRISPR reaction components include Cas12a protein, crRNA, and an RNase inhibitor; the crRNA contains a guide sequence that matches the Cas12a activation region in the specific aptamer and can form a Cas12a-crRNA complex with the Cas12a protein; the Cas12a-crRNA complex can recognize and be activated by the free-state specific aptamer, and the activated Cas12a-crRNA complex has trans-cleavage activity; under the same reaction conditions and a predetermined reaction time, the more free-state specific aptamers there are, the higher the number or proportion of activated Cas12a-crRNA complexes, and the higher the degree of cleavage by the dual-labeled DNA reporter probe. The dual-labeled DNA reporter probe has one end labeled with FAM (fluorescein) and the other end labeled with biotin, and can be trans-cleaved by the activated Cas12a-crRNA complex. The amount of the dual-labeled DNA reporter probe is excessive, that is, NT-proBNP is not present in the reaction system, all specific aptamers remain in a free state, the Cas12a protein is activated to the maximum extent, the cleavage ratio of the dual-labeled DNA reporter probe is still less than 100%, and after the reaction, a sufficient amount of intact dual-labeled DNA reporter probe is still retained in the system, thereby ensuring that some dual-labeled DNA reporter probes are cleaved and some dual-labeled DNA reporter probes remain intact. A reaction buffer is used to reconstitute the specific aptamer, the CRISPR reaction components, and the dual-labeled DNA reporter probe, dilute the urine sample, and provide the reaction conditions required for the aptamer-NT-proBNP binding reaction and the Cas12a-crRNA complex cleavage reaction. The reaction conditions include the reaction environment required for the specific aptamer to specifically bind to NT-proBNP, and the buffer conditions and metal ions required for the Cas12a-crRNA complex to cleave the dual-labeled DNA reporter probe. And a lateral chromatography test strip, including a conjugation pad, a control line (C line), and a test line (T line); the conjugation pad is immobilized with colloidal gold-labeled anti-FITC / FAM antibody, the control line is coated with streptavidin, and the test line is coated with a secondary antibody against the anti-FITC / FAM antibody; wherein, NT-proBNP in the urine sample binds to a portion of the specific aptamer to form an aptamer-NT-proBNP complex, and the unbound free specific aptamer is recognized by the Cas12a-crRNA complex, activating a portion of the Cas12a-crRNA complex. The activated Cas12a-crRNA complex cleaves the dual-labeled DNA reporter probe, and the activated Cas12a-crRNA... The higher the quantity or proportion of the complex, the higher the degree of cleavage of the dual-labeled DNA reporter probe. The uncleaved dual-labeled DNA reporter probe binds to the colloidal gold-labeled anti-FITC / FAM antibody and is captured by streptavidin at the C-line via biotin at its end. The cleaved fragment carrying the FAM label binds to the colloidal gold-labeled anti-FITC / FAM antibody, cannot be captured by streptavidin at the control line, and continues to migrate to the detection line where it is captured by the secondary antibody. The color intensity of the control line of the lateral chromatography test strip reflects the amount of uncleaved dual-labeled DNA reporter probe, and the color intensity of the detection line reflects the amount of cleaved fragment carrying the FAM label. The NT-proBNP concentration is quantitatively reflected by the ratio of the color intensity of the control line to the detection line.

[0008] When detecting NT-proBNP concentration in urine, the target nucleotide NT-proBNP is not directly recognized by the CRISPR reaction component. Through the over-design of the specific aptamer, after the urine sample and the specific aptamer are mixed in the reaction buffer, a portion of the total amount of the specific aptamer binds to NT-proBNP in the urine sample to form an aptamer-NT-proBNP complex, while the remaining portion remains in a free state, forming a reaction solution containing both the free specific aptamer and the aptamer-NT-proBNP complex. After the CRISPR reaction component and the dual-labeled DNA reporter probe are added to the reaction solution, the crRNA forms a Cas12a-crRNA complex with the Cas12a protein, and the free specific aptamer is bound by the Cas12a protein. The α-crRNA complex recognizes and activates the Cas12α-crRNA complex, which then cleaves the dual-labeled DNA reporter probe. The degree of cleavage of the dual-labeled DNA reporter probe is positively correlated with the amount of free specific aptamers, and the amount of free specific aptamers decreases monotonically with increasing NT-proBNP concentration in the urine sample. This ensures a predetermined monotonic correspondence between the degree of cleavage of the dual-labeled DNA reporter probe and the NT-proBNP concentration within the detection range of the kit, where the cleavage ratio of the dual-labeled DNA reporter probe is less than 100%. This converts NT-proBNP concentration information into information on the quantity of free specific aptamers that can be recognized by the CRISPR reaction components, enabling quantitative detection of the degree of cleavage of the dual-labeled DNA reporter probe by the lateral chromatography test strip.

[0009] In detecting NT-proBNP concentration in urine, the kit uses a dual-labeled DNA reporter probe as a substrate for the CRISPR / Cas12a signal transduction reaction. Its working principle is as follows: after the Cas12a-crRNA complex is activated by a free, specific aptamer, it initiates trans-cleavage activity, non-specifically cleaving the dual-labeled DNA reporter probe to produce a free FAM-labeled fragment. This free FAM fragment is captured by the anti-FAM antibody secondary antibody on the detection line of the lateral chromatography strip, resulting in color development. The intact, uncleaved dual-labeled DNA reporter probe is captured by the control line of the lateral chromatography strip through biotin-streptavidin interaction, also resulting in color development. Therefore, the degree of cleavage of the dual-labeled DNA reporter probe directly determines the ratio of color intensity (signal intensity) between the detection line and the control line of the lateral chromatography strip, which is the key material basis for achieving quantitative detection of NT-proBNP concentration.

[0010] The reason why the dual-labeled DNA reporter probe is designed in excess in this invention is mainly based on the following considerations: First, ensure the control line of the lateral chromatography test strip is valid. The control line of the lateral chromatography test strip is colored by streptavidin capturing the biotin end of the intact dual-labeled DNA reporter probe (FAM-Biotin). If the dual-labeled DNA reporter probe is cleaved and depleted, the control line will not be colored, the validity of the lateral chromatography test strip cannot be verified, and the test results are unreliable.

[0011] Second, maintaining the linearity of the quantitative relationship. The degree of cleavage of the dual-labeled DNA reporter probe is positively correlated with the amount of free specific aptamers, while the amount of free specific aptamers decreases monotonically with increasing NT-proBNP concentration. If the dual-labeled DNA reporter probe is insufficient, in the presence of high concentrations of free specific aptamers (corresponding to urine samples with low concentrations of NT-proBNP), the dual-labeled DNA reporter probe will be completely cleaved, and the degree of cleavage will no longer reflect the change in the amount of free specific aptamers, leading to the failure of the quantitative relationship and a compression of the detection upper limit.

[0012] Third, it ensures the integrity of the detection range. The excess of dual-labeled DNA reporter probes ensures that the degree of cleavage maintains a monotonic correspondence with the NT-proBNP concentration throughout the entire detection range of the kit (from the lower limit of detection to the upper limit of detection), avoiding signal saturation due to substrate depletion.

[0013] This invention employs a target concentration-dependent negative signal transduction mechanism. In the absence of NT-proBNP, the specific aptamer exists in a free state, and its Cas12a activation region can be recognized by the Cas12a-crRNA complex, resulting in a high level of trans-cleavage activity of the Cas12a-crRNA complex and a correspondingly high degree of cleavage by the dual-labeled DNA reporter probe. As the NT-proBNP concentration increases, the number of aptamer-NT-proBNP complexes formed gradually increases, and the number of free-state specific aptamers participating in the Cas12a-crRNA complex activation process gradually decreases. Consequently, the trans-cleavage activity of the Cas12a-crRNA complex decreases, and the degree of cleavage by the dual-labeled DNA reporter probe decreases. This negative signal conversion mechanism achieves specific recognition of NT-proBNP and CRISPR / Cas12a signal conversion in a liquid-phase mixture. It eliminates the need for separately designed trigger strands, aptamer complementary strands, blocking strands, or auxiliary nucleic acid strands such as blockers, bandages, scaffolds, and fuels for multi-stage strand substitution reactions, and also eliminates the need to construct a solid-phase aptamer-cDNA recognition interface and perform washing and separation. This reduces the types of auxiliary nucleic acid strands, reaction components, and operational steps, lowers the possibility of competition between nucleic acid sequences and unexpected strand substitutions, shortens the signal conversion path, and reduces the possibility of background signals due to non-specific release of the trigger strand. Simultaneously, through specific aptamers, crRNA, Cas12a protein, and dual-labeled DNA reporter probes, changes in NT-proBNP concentration can be converted into continuous changes in the number of free specific aptamers and the degree of cleavage by the dual-labeled DNA reporter probe, thereby establishing a correlation between the degree of cleavage by the dual-labeled DNA reporter probe and the NT-proBNP concentration, enabling the detection of NT-proBNP concentration in urine. Under theoretical limiting conditions, when NT-proBNP is absent in the system and other reaction components are sufficient, the activation of the Cas12a-crRNA complex mediated by the free aptamer and the cleavage of the dual-labeled DNA reporter probe tend to be at their maximum; when the aptamer is fully occupied by NT-proBNP, the activation of the Cas12a-crRNA complex mediated by the free aptamer and the cleavage of the dual-labeled DNA reporter probe tend to be at their minimum.

[0014] Micro-thermophoresis results showed that the specific aptamer could bind to both NT-proBNP and crRNA. The equilibrium dissociation constant between the specific aptamer and NT-proBNP was 1155 ± 24 nM, and the equilibrium dissociation constant between the specific aptamer and crRNA was 10674 ± 280 nM. Under the detection conditions of this invention, the apparent binding affinity of the specific aptamer to NT-proBNP was higher than its apparent binding affinity to crRNA. This result provides experimental evidence that binding to the specific aptamer reduces the number of free-state specific aptamers capable of participating in crRNA recognition and Cas12a protein activation.

[0015] This invention utilizes the dosage of specific aptamers, CRISPR reaction components, and dual-labeled DNA reporter probes to convert the binding of NT-proBNP to the specific aptamer into a change in the trans-cleavage activity of the Cas12a-crRNA complex. The partitioning relationship between the bound and free specific aptamers is characterized by the degree of cleavage by the dual-labeled DNA reporter probe. By pre-calibrating the correlation between the color intensity ratio (signal intensity) of the detection line and control line of the lateral chromatography test strip, which represents the degree of cleavage by the dual-labeled DNA reporter probe, and the NT-proBNP concentration, the concentration of NT-proBNP in the urine sample to be tested can be determined based on this ratio.

[0016] Unlike positive signal transduction methods that rely on target binding followed by trigger release, exposure of trigger sequences, or initiation of aptamer-cDNA strand displacement reactions, this invention does not use NT-proBNP-induced generation or release of additional trigger chains as activation conditions for the Cas12a-crRNA complex. Instead, it directly uses the free, unbound specific aptamers as the activation conditions for the Cas12a-crRNA complex. In the absence of NT-proBNP, the number of free, specific aptamers is high, resulting in high trans-cleavage activity of the Cas12a-crRNA complex and high cleavage degree of the dual-labeled DNA reporter probe. As the NT-proBNP concentration increases, the number of free, specific aptamers decreases, leading to a decrease in the trans-cleavage activity of the Cas12a-crRNA complex and a lower cleavage degree of the dual-labeled DNA reporter probe, thus forming a cleavage degree of the dual-labeled DNA reporter probe that is negatively correlated with the NT-proBNP concentration.

[0017] Preferably, the kit further includes reaction tubes; each reaction tube includes a tube body and a cap for sealing the tube body; the specific aptamer is pre-loaded in the tube body in lyophilized powder form, and the CRISPR reaction component and the dual-labeled DNA reporter probe are both pre-loaded in the cap body in lyophilized powder form; the reaction buffer is individually packaged. Thus, the specific aptamer is spatially separated from the CRISPR reaction component and the dual-labeled DNA reporter probe. During detection, the urine sample to be tested first undergoes a specific recognition reaction with the specific aptamer in the reaction buffer, and then the CRISPR reaction component and the dual-labeled DNA reporter probe are added, triggering a Cas12a signal conversion reaction, thereby allowing the target recognition reaction and the Cas12a signal conversion reaction to proceed in a predetermined order.

[0018] Preferably, the cap is a rotary cap, which, when rotated, releases the CRISPR reaction components and the dual-labeled DNA reporter probe, allowing them to fall into the tube and mix with the reconstituted specific aptamer.

[0019] Preferably, based on a single reaction, the amount of the specific aptamer is 1.5–15 pmol, the amount of the crRNA is 3.25–13 pmol, the molar ratio of the Cas12a protein to the crRNA is 1:1–4:1, and the amount of the RNase inhibitor added is 20–80 U.

[0020] Preferably, the molar ratio of the specific aptamer, the dual-labeled DNA reporter probe, the Cas12a protein, and the crRNA is 1:4:2:1.

[0021] Preferably, based on a single reaction, the amount of the specific aptamer is 6.5 pmol, the amount of RNase inhibitor added is 40 U, ​​the volume of the reaction buffer is 58 μL, and the volume ratio of the reaction buffer to the urine sample to be tested is 29:1.

[0022] Preferably, the sequence of the specific aptamer is: 5'-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3'; the sequence of the crRNA is: 5'-UAAUUUCUACUAAGUGUAGAUCCGGUCUACGGUGGACAGUUUCCA-3'; and the sequence of the dual-labeled DNA reporter probe is: 5'-FAM-TTTTTTTTAAATTTTTTTTT-Biotin-3'.

[0023] Preferably, the kit further includes a handheld detector, which is used to read the signal intensity of the test line and the control line of the lateral chromatography test strip, calculate the signal intensity ratio of the control line to the test line of the lateral chromatography test strip, and obtain the corresponding NT-proBNP concentration according to the NT-proBNP concentration standard curve.

[0024] Preferably, the handheld detector includes: An optical sensing module is used to scan the control line and the detection line of the lateral chromatography test strip and to quantify the signal intensity of the control line and the detection line of the lateral chromatography test strip. The data processing module is pre-stored with an NT-proBNP concentration standard curve, which is used to calculate the signal intensity ratio between the control line and the detection line of the lateral chromatography test strip, and substitute the signal intensity ratio into the NT-proBNP concentration standard curve to obtain the corresponding NT-proBNP concentration.

[0025] Furthermore, the kit is used in the preparation of heart failure assessment products.

[0026] Compared with the prior art, the advantages of the present invention are as follows: (i) Direct detection of urine samples, non-invasive and convenient. This invention uses a specific aptamer to identify NT-proBNP in urine, achieving completely non-invasive sample detection. It avoids the pain and inconvenience of repeated venous blood collection, is suitable for heart failure patients who require long-term monitoring, and facilitates home monitoring and community screening.

[0027] (II) CRISPR / Cas12a signal amplification, with sensitivity meeting the requirements for urine detection. This invention utilizes the signal amplification function of the CRISPR / Cas12a system. After the free-state specific aptamer activates the Cas12a-crRNA complex, it trans-cleaves the dual-labeled DNA reporter probe, achieving cascaded signal amplification. The sensitivity and specificity meet the detection requirements for low concentrations of NT-proBNP in urine.

[0028] (III) No large equipment required, simple operation. This invention reads results through lateral chromatography test strips, eliminating the need for large equipment such as enzyme-linked immunosorbent assay (ELISA) readers and chemiluminescence immunoassay analyzers. It has low professional requirements for operators, short testing cycle, and is suitable for POCT scenarios such as home monitoring, community healthcare, and rapid triage in emergency departments.

[0029] (iv) The reaction components can be lyophilized and have good stability. The specific aptamers, CRISPR reaction components and dual-labeled DNA reporter probes are all pre-packaged in lyophilized powder form, which can be stably stored and transported at room temperature without the need for a cold chain, significantly reducing the storage and transportation costs of the kit.

[0030] (V) Differential affinity design between specific aptamers and crRNA ensures a wide range of dynamic responses. Micro-thermophoretic detection results show that the equilibrium dissociation constant of the specific aptamer selected in this invention with NT-proBNP (1155±24 nM) is significantly lower than that with crRNA (10674±280 nM). That is, the apparent binding affinity of the specific aptamer with NT-proBNP is higher than that with crRNA. This differential affinity design ensures that NT-proBNP can preferentially bind to the specific aptamer, thereby achieving a monotonically decreasing signal response with target concentration within the detection range, avoiding signal distortion caused by excessive competition of the specific aptamer by crRNA.

[0031] In summary, this invention does not rely on blood samples, large equipment, or professional operation. It is applicable to urine samples and non-laboratory scenarios, and can meet the application needs of bedside point-of-care testing scenarios such as home monitoring, community healthcare, and rapid triage in emergency departments. Attached Figure Description

[0032] Figure 1 This is a schematic diagram of the detection process of the urine NT-proBNP concentration detection kit based on aptamer-mediated CRISPR / Cas12a signal transduction of the present invention; wherein, Biotin-DNA-FAM represents a dual-labeled DNA reporter probe; Figure 2 The images show the results of micro-thermophoresis detection of the specific aptamer labeled with Cy5 in Example 1 binding to crRNA and NT-proBNP, respectively; A shows the results of micro-thermophoresis detection of the specific aptamer labeled with Cy5 binding to crRNA, and B shows the results of micro-thermophoresis detection of the specific aptamer labeled with Cy5 binding to NT-proBNP; Cy5-APT represents the specific aptamer labeled with Cy5. Figure 3 The bar chart shows the optimal fluorescence intensity of the NT-proBNP group and the control group under different specific aptamer concentrations in Example 2, and the line graph shows the maximum fluorescence intensity difference between the two groups. Figure 4 The graphs show the fluorescence kinetics of the reaction system under different NT-proBNP concentrations in Example 3, as well as the linear fitting curve between the rate of change of fluorescence intensity and the logarithm of the NT-proBNP concentration. Figure 5 The bar chart shows the optimal fluorescence intensity of the control group, CK-MB group, H-FABP group, cTnI group, BNP group and NT-proBNP group in Example 4. Figure 6The images show the color development results of the lateral chromatography test strips under different NT-proBNP concentrations in Example 5, as well as the standard curve between the C / T ratio of the lateral chromatography test strips and the logarithm of the NT-proBNP concentration. Detailed Implementation

[0033] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and specific embodiments. It should be understood that the specific embodiments described herein are merely intended to explain the invention and not to limit it. Those skilled in the art will recognize that the invention can be practiced without some of these specific details. The following description of the embodiments is merely to provide a better understanding of the invention by illustrating examples of it.

[0034] It should be noted that, in this document, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Unless otherwise specified, an element defined by the phrase "comprising..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.

[0035] Example 1: MST (microscale thermophoresis) was used to determine the binding ability of specific aptamers to NT-proBNP and crRNA.

[0036] In this embodiment, MST was used to determine the binding affinity between the specific aptamer and NT-proBNP, as well as between the specific aptamer and crRNA.

[0037] NT-proBNP solutions of different concentrations were mixed with equal volumes of Cy5-labeled specific aptamer solutions to obtain 15 NT-proBNP binding reaction systems; crRNA solutions of different concentrations were mixed with equal volumes of Cy5-labeled specific aptamer solutions to obtain 15 crRNA binding reaction systems, for a total of 30 reaction systems.

[0038] NT-proBNP solution was prepared by mixing NT-proBNP with reaction buffer, and Cy5 fluorescently labeled specific aptamer solution was prepared by mixing Cy5 fluorescently labeled specific aptamer with reaction buffer. The reaction buffer consisted of 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, and 100 μg / mL recombinant albumin. The Cy5 fluorescently labeled specific aptamer sequence was: 5'-Cy5-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3'.

[0039] In 15 NT-proBNP binding reaction systems, the NT-proBNP concentrations were 0.13, 0.26, 0.52, 2.1, 4.2, 8.4, 16.8, 33.6, 67.19, 134.38, 268.75, 537.5, 1075, 2150, and 4300 nM, respectively. In 15 crRNA binding reaction systems, the crRNA concentrations were 1.53, 3.05, 6.10, 12.21, 24.41, 48.83, 97.66, 195.31, 390.63, 781.25, 1562.5, 3125, 6250, 12500, and 50000 nM, respectively. In all 30 reaction systems, the concentration of the Cy5 fluorescently labeled specific aptamer was 20 nM.

[0040] The reaction systems were then loaded into MST capillaries and detected using a NanoTemper NT.115 microthermophoresis apparatus. The normalized fluorescence values ​​(Fnorm) under each concentration condition were recorded. Binding curves were plotted with the NT-proBNP concentration or crRNA concentration in the reaction system as the x-axis and the normalized fluorescence value (Fnorm) as the y-axis, with the x-axis using a logarithmic scale to base 10. Based on the 1:1 binding model, a nonlinear fitting was performed using a quadratic equation of the mass action law considering the concentration of specific aptamers with Cy5 fluorescent labeling and ligand consumption, as shown in equation (1). (1); In equation (1), X represents the concentration of NT-proBNP or crRNA, T represents the concentration of the Cy5 fluorescently labeled specific aptamer, and the value is 20 nM. free The normalized fluorescence value, F, represents the free state of the specific aptamer. bound K represents the normalized fluorescence value when the Cy5-labeled specific aptamer forms a bound state with NT-proBNP or crRNA. D This represents the equilibrium dissociation constant.

[0041] MST detection results showed that with increasing NT-proBNP concentration, the normalized fluorescence value of the Cy5-labeled specific aptamer changed in a concentration-dependent manner, forming a corresponding binding curve. Through nonlinear fitting, the equilibrium dissociation constant between the Cy5-labeled specific aptamer and NT-proBNP was determined to be: K D =1155±24 nM; indicating that the specific aptamer can bind to NT-proBNP. With increasing crRNA concentration, the normalized fluorescence value of the Cy5-labeled specific aptamer generally decreased, forming a concentration-dependent binding curve. After nonlinear fitting, the equilibrium dissociation constant between the Cy5-labeled specific aptamer and crRNA was: K D =10674±280 nM.

[0042] The MST assay results above indicate that the specific aptamer can bind to both NT-proBNP and crRNA. The K-axis between the specific aptamer and NT-proBNP... D Approximately K between it and crRNA D The ratio of 1 / 9.24 indicates that, under the detection conditions of this embodiment, the specific aptamer exhibits a higher epigenetic binding affinity for NT-proBNP. Furthermore, the MST results also show that the binding of NT-proBNP to the specific aptamer can affect the interaction between the free specific aptamer and crRNA. Combined with subsequent experiments, this demonstrates that the binding of NT-proBNP to the specific aptamer reduces the number of free specific aptamers that can participate in the crRNA-mediated activation of the Cas12a-crRNA complex, thereby reducing the activation level of the Cas12a-crRNA complex.

[0043] The results of micro-thermophoresis detection of the binding of Cy5 fluorescently labeled specific aptamers to crRNA and NT-proBNP are shown in the figure below. Figure 2 As shown in the figure, A represents the micro-thermophoretic detection results of the binding of Cy5 fluorescently labeled specific aptamer to crRNA. The final concentration of Cy5 fluorescently labeled specific aptamer is 20 nM, the x-axis represents the final concentration of crRNA, and the y-axis represents the normalized fluorescence value Fnorm. After nonlinear fitting, the equilibrium dissociation constant between Cy5 fluorescently labeled specific aptamer and crRNA is K. D=10674±280 nM. Figure B shows the micro-thermophoretic detection results of the binding of the Cy5 fluorescently labeled specific aptamer to NT-proBNP. The final concentration of the Cy5 fluorescently labeled specific aptamer was 20 nM. The x-axis represents the final concentration of NT-proBNP, and the y-axis represents the normalized fluorescence value Fnorm. After nonlinear fitting, the equilibrium dissociation constant between the Cy5 fluorescently labeled specific aptamer and NT-proBNP was K. D =1155±24 nM.

[0044] Example 2: This example illustrates the optimal concentration of the specific aptamer during the reaction process and provides a method for optimizing the concentration of the specific aptamer. The reaction buffer used in this example is the same as that in Example 1.

[0045] The method in this embodiment includes the following steps: Step 1: Specific recognition response. Four specific aptamer concentration groups were set up. Each specific aptamer concentration group included one NT-proBNP group and one control group, that is, there were four NT-proBNP groups and four control groups.

[0046] A working solution of NT-proBNP with a concentration of 6 ng / mL was prepared. Four specific aptamer solutions with concentrations of 300 nM, 600 nM, 1.2 μM, and 3 μM were also prepared. The NT-proBNP working solution was prepared by mixing NT-proBNP with the reaction buffer, and the specific aptamer solutions were prepared by mixing the specific aptamer with the reaction buffer.

[0047] For the four NT-proBNP groups: Take 5 μL of NT-proBNP working solution with a concentration of 6 ng / mL, and add 5 μL of specific aptamer solutions with concentrations of 300 nM, 600 nM, 1.2 μM and 3 μM respectively. Mix well to obtain four NT-proBNP and specific aptamer mixed solutions with a volume of 10 μL each, which are the four NT-proBNP groups.

[0048] For the four control groups: Take 5 μL of reaction buffer and add 5 μL of specific aptamer solutions with concentrations of 300 nM, 600 nM, 1.2 μM and 3 μM respectively. Mix well to obtain four 10 μL specific aptamer control solutions, which are the four control groups.

[0049] Within the same specific aptamer concentration group, the NT-proBNP group and the control group had the same concentration of specific aptamer solution.

[0050] The sequence of the specific aptamer is: 5'-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3'.

[0051] Step 2: CRISPR / Cas12a signal amplification response.

[0052] Eight 10 μL CRISPR / Cas12a mixtures were prepared. Each mixture contained 300 nM crRNA, 600 nM Cas12a protein, and 40 U of RNase inhibitor. The remaining volume was made up with reaction buffer. The eight mixtures were incubated at 37 °C for 15 min to obtain eight incubated CRISPR / Cas12a mixtures. The crRNA sequence was: 5′-UAAUUUCUACUAAGUGUAGAUCCGGUCUACGGUGGACAGUUUCCA-3′.

[0053] Add 10 μL of the incubated CRISPR / Cas12a mixture to each of the eight reaction groups obtained in step 1, followed by 10 μL of a 3 μM dual-labeled DNA reporter probe solution, forming eight 30 μL reaction systems. The dual-labeled DNA reporter probe solution was prepared by mixing the dual-labeled DNA reporter probe with the reaction buffer. The dual-labeled DNA reporter probe is labeled with the fluorescent dye Texas Red at one end and the quencher BHQ2 at the other end, with the sequence: 5'-TexasRed-TTTTTTTTAAATTTTTTTTT-BHQ2-3'. This dual-labeled DNA reporter probe is a Texas Red-BHQ2 fluorescence-quenched DNA reporter probe.

[0054] The eight reaction systems were mixed thoroughly to ensure that the components in each system reacted completely, resulting in eight reaction solutions.

[0055] Step 3: Signal measurement.

[0056] Eight reaction solutions were placed in a real-time fluorescence quantitative PCR instrument for real-time fluorescence detection. The sampling period was 1 minute and the detection time was 60 minutes to obtain the fluorescence kinetic curves of each reaction solution.

[0057] For each specific aptamer concentration group, the difference in fluorescence intensity (i.e., signal intensity) between the NT-proBNP group and the control group at each sampling time was calculated. The maximum fluorescence intensity difference obtained during the detection process was used as the evaluation index to characterize the detection performance of that specific aptamer concentration group under specific aptamer concentration conditions. The fluorescence intensity of the NT-proBNP group and the fluorescence intensity of the control group at the sampling time corresponding to the maximum fluorescence intensity difference were defined as the optimal fluorescence intensity of the NT-proBNP group and the optimal fluorescence intensity of the control group, respectively.

[0058] A graph showing the optimization results of specific aptamer concentrations was plotted based on the fluorescence intensity differences corresponding to each specific aptamer concentration group, such as... Figure 3 As shown.

[0059] Figure 3 The fluorescence response of the NT-proBNP group and the control group under different specific aptamer concentrations is shown. The bar chart represents the optimal fluorescence intensity of the NT-proBNP group and the control group under different specific aptamer concentrations, and the line graph represents the maximum fluorescence intensity difference between the NT-proBNP group and the control group. In the figure, APT 50 nM, APT 100 nM, APT 200 nM, and APT 500 nM correspond to the NT-proBNP group and the control group with specific aptamer concentrations of 300 nM, 600 nM, 1.2 μM, and 3 μM, respectively. Figure 3 The results show that, using the maximum fluorescence intensity difference between the control group and the NT-proBNP group as an evaluation index, the highest maximum fluorescence intensity difference was obtained when the final concentration of the specific aptamer was 100 nM.

[0060] The larger difference in maximum fluorescence intensity indicates that the NT-proBNP group and the control group have higher signal discrimination and a larger detection window under the final concentration of this specific aptamer, which is beneficial to improving the detection performance of the system for the target analyte NT-proBNP. Therefore, 100 nM was determined as the optimal final concentration of the specific aptamer and used in subsequent experiments.

[0061] In this embodiment, a Texas Red-BHQ2 fluorescent-quenched DNA reporter probe is used for fluorescence detection. In other embodiments using lateral chromatography test strips, a FAM-Biotin lateral chromatography dual-labeled DNA reporter probe is used. Both reporter probes have the same nucleotide sequence and can serve as trans-cleavage substrates for the activated Cas12a-crRNA complex; however, their end-labeling groups are selected based on the different detection signal readout methods. Specifically, the Texas Red-BHQ2 fluorescent-quenched DNA reporter probe is used to convert the degree of cleavage into a change in fluorescence signal, while the FAM-Biotin lateral chromatography dual-labeled DNA reporter probe is used to convert the degree of cleavage into changes in the detection line and control line signals on the lateral chromatography test strip.

[0062] Example 3: This example illustrates the detection range of NT-proBNP concentration in the specific aptamer / CRISPR / Cas12a detection system and provides a method for detecting the NT-proBNP concentration range. The reaction buffer used in this example is the same as in Example 1.

[0063] The method in this embodiment includes the following steps: Step 1: Specific recognition response.

[0064] Eight mixed solutions of NT-proBNP and specific aptamers at different concentrations were prepared.

[0065] Take 5 μL of NT-proBNP working solution with concentrations of 0 pg / mL, 6 pg / mL, 30 pg / mL, 60 pg / mL, 300 pg / mL, 600 pg / mL, 3000 pg / mL, and 6000 pg / mL, respectively. Add 5 μL of a 600 nM specific aptamer solution to each NT-proBNP working solution, mix thoroughly, and obtain eight 10 μL mixed solutions. The 0 pg / mL NT-proBNP working solution served as a blank control, acting as a reaction buffer without NT-proBNP. The NT-proBNP working solution was prepared by resolving NT-proBNP with the reaction buffer, and the specific aptamer solution was prepared by resolving the specific aptamer with the reaction buffer. The sequence of the specific aptamer is: 5′-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3′.

[0066] Step 2: CRISPR / Cas12a signal amplification response.

[0067] Eight 10 μL CRISPR / Cas12a mixtures were prepared. In each mixture, the concentration of crRNA was 300 nM, the concentration of Cas12a protein was 600 nM, and the amount of RNase inhibitor added was 40 U. The remaining volume was made up with reaction buffer. The sequence of crRNA was: 5'-UAAUUUCUACUAAGUGUAGAUCCGGUCUACGGUGGACAGUUUCCA-3'.

[0068] Eight CRISPR / Cas12a mixtures were incubated at 37 °C for 15 min to obtain eight incubated CRISPR / Cas12a mixtures.

[0069] Add 10 μL of the incubated CRISPR / Cas12a mixture to each of the eight mixed solutions obtained in step 1, followed by 10 μL of a 3 μM dual-labeled DNA reporter probe solution, forming eight 30 μL reaction systems. The dual-labeled DNA reporter probe is labeled with the fluorescent dye Texas Red at one end and the quencher BHQ2 at the other end, with the sequence: 5'-Texas Red-TTTTTTTTAAATTTTTTTTT-BHQ2-3'. The dual-labeled DNA reporter probe solution was prepared by mixing the dual-labeled DNA reporter probe with the reaction buffer.

[0070] The eight reaction systems were mixed thoroughly to allow the components in each system to react completely, resulting in eight reaction solutions.

[0071] Step 3: Signal measurement.

[0072] Eight reaction solutions were placed in a real-time fluorescence quantitative PCR instrument for detection. The sampling period was 1 min, and the detection time was 60 min. The fluorescence kinetic curves of each reaction solution were obtained, as shown below. Figure 4 As shown.

[0073] Figure 4In this context, NT represents NT-proBNP, and APT represents the specific aptamer. NT+APT (NT 0 pg / mL) represents the detection result of a reaction solution with an NT-proBNP concentration of 0 pg / mL; NT+APT (NT 1 pg / mL) represents the detection result of a reaction solution with an NT-proBNP concentration of 1 pg / mL; NT+APT (NT 5 pg / mL) represents the detection result of a reaction solution with an NT-proBNP concentration of 5 pg / mL; NT+APT (NT 10 pg / mL) represents the detection result of a reaction solution with an NT-proBNP concentration of 10 pg / mL; NT+APT (NT 50 pg / mL) represents the detection result of a reaction solution with an NT-proBNP concentration of 50 pg / mL; NT+APT (NT 100 pg / mL) represents the detection result of a reaction solution with an NT-proBNP concentration of 100 pg / mL; and NT+APT (NT 500 pg / mL) represents the detection result of a reaction solution with an NT-proBNP concentration of 500 pg / mL. The detection results of the reaction solution are pg / mL; NT+APT (NT 1000 pg / mL) indicates the detection results of the reaction solution with an NT-proBNP concentration of 1000 pg / mL.

[0074] Depend on Figure 4 It is evident that the fluorescence intensity of the reaction solution gradually decreases with increasing NT-proBNP concentration, and different concentrations of NT-proBNP can produce distinguishable fluorescence intensity signals. Within the NT-proBNP concentration range of 1 pg / mL to 1000 pg / mL, the rate of change in fluorescence intensity correlates with the logarithm of the NT-proBNP concentration lg(C). NT-proBNP The two molecules exhibit a good linear relationship, with the linear regression equation being: y = 7.092x + 3.2662, and the coefficient of determination R0. 2 =0.9968. Where y is the fluorescence intensity change rate ΔI / I0, and x is the logarithm of the NT-proBNP concentration lg(C NT-proBNP ).

[0075] The reaction group with an NT-proBNP concentration of 0 pg / mL was used as a blank control group. Based on the standard deviation of the fluorescence response values ​​obtained from repeated detections in this group, the detection limit was determined using the 3σ principle. Combined with the linear regression equation described above, the corresponding NT-proBNP concentration was calculated, resulting in a detection limit of 504 fg / mL for NT-proBNP in this embodiment. These results indicate that the specific aptamer / CRISPR / Cas12a detection system constructed in this embodiment exhibits good linear detection capability for NT-proBNP within a concentration range of 1 pg / mL to 1000 pg / mL, achieving highly sensitive detection of NT-proBNP concentration.

[0076] Example 4: This example illustrates the specificity of NT-proBNP concentration detection using a specific aptamer / CRISPR / Cas12a method and provides a method for verifying the specificity of NT-proBNP concentration detection. The reaction buffer used in this example is the same as in Example 1.

[0077] The method in this embodiment includes the following steps: Step 1: Specific recognition response.

[0078] Five experimental groups were set up: CK-MB, H-FABP, cTnI, BNP, and NT-proBNP, along with one control group. The CK-MB group received working solution of creatine kinase-MB (CK-MB); the H-FABP group received working solution of heart-type fatty acid-binding protein (H-FABP); the cTnI group received working solution of cardiac troponin I (cTnI); the BNP group received working solution of B-type natriuretic peptide (BNP); the NT-proBNP group received working solution of N-terminal pro-B-type natriuretic peptide (NT-proBNP); and the control group received no working solution of any of the above proteins but an equal volume of reaction buffer.

[0079] Working solutions of CK-MB, H-FABP, cTnI, BNP, and NT-proBNP at concentrations of 6 ng / mL, and a specific aptamer solution at a concentration of 600 nM were prepared. The CK-MB, H-FABP, cTnI, BNP, NT-proBNP, and specific aptamer solutions were prepared by reacting CK-MB, H-FABP, cTnI, BNP, NT-proBNP, and specific aptamer with reaction buffer, respectively. The sequence of the specific aptamer is: 5'-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3'.

[0080] For the five experimental groups: 5 μL of CK-MB, H-FABP, cTnI, BNP, and NT-proBNP working solutions with a concentration of 6 ng / mL were taken, and 5 μL of a specific aptamer solution with a concentration of 600 nM was added to each working solution. The solutions were mixed thoroughly to obtain the CK-MB, H-FABP, cTnI, BNP, and NT-proBNP groups, respectively. The volume of each group was 10 μL.

[0081] For the control group: Take 5 μL of reaction buffer and add 5 μL of a specific aptamer solution with a concentration of 600 nM. Mix well to obtain a control group with a volume of 10 μL.

[0082] Step 2: CRISPR / Cas12a signal amplification response.

[0083] Six 10 μL CRISPR reaction mixtures were prepared. In each CRISPR reaction mixture, the crRNA concentration was 300 nM, the Cas12a protein concentration was 600 nM, the RNase inhibitor enzyme activity was 40 U, ​​and the remaining volume was made up with reaction buffer.

[0084] The CRISPR reaction mixture was incubated at 37 °C for 15 min to obtain the incubated CRISPR reaction mixture.

[0085] Add 10 μL of the incubated CRISPR reaction mixture to the control group and five experimental groups obtained in step 1, and then add 10 μL of a 3 μM dual-labeled DNA reporter probe solution to each group, forming six reaction systems, each with a volume of 30 μL. The dual-labeled DNA reporter probe is labeled with the fluorescent dye Texas Red at one end and the quencher BHQ2 at the other end, with the sequence: 5'-Texas Red-TTTTTTTTAAATTTTTTTTT-BHQ2-3'. The dual-labeled DNA reporter probe solution is prepared by mixing the dual-labeled DNA reporter probe with the reaction buffer.

[0086] The six reaction systems were mixed thoroughly to allow their components to react completely, resulting in six reaction solutions.

[0087] Step 3: Signal measurement.

[0088] Six reaction solutions were placed on a real-time PCR instrument, with a sampling period of 1 minute and a detection time of 60 minutes, to obtain the fluorescence kinetic curves of each reaction solution.

[0089] The fluorescence intensity at the 10th minute of the detection process was taken as the optimal fluorescence intensity for each experimental group and the control group. One-way ANOVA was used to statistically analyze the differences between the experimental groups and the control group. A plot was drawn based on the optimal fluorescence intensity of each experimental group and the control group. Figure 5 The image shows the specific detection results. Figure 5 The fluorescence response of the detection system under different protein conditions is shown, and the bar chart represents the optimal fluorescence intensity of the control group and each experimental group. Figure 5 The results show that the optimal fluorescence intensity of the CK-MB group, H-FABP group, cTnI group and BNP group is close to that of the control group, while the optimal fluorescence intensity of the NT-proBNP group is significantly lower than that of the control group and other experimental groups.

[0090] Using fluorescence intensity as the evaluation index between the control group and each experimental group, the fluorescence intensity of the CK-MB group, H-FABP group, cTnI group, and BNP group was similar to that of the control group, while the fluorescence intensity of the NT-proBNP group was significantly lower than that of the control group and other protein groups. The bar chart showed a significant difference in fluorescence intensity between the NT-proBNP group and the control group; statistical analysis showed that the difference between the NT-proBNP group and the control group was statistically significant. (p < 0.01). Here, p is the probability value of the statistical significance test, used to evaluate whether the difference between groups is statistically significant; p < 0.01 indicates that the difference between groups is statistically significant, that is, the probability that the difference is caused by random factors is less than 1%; the symbol " "" indicates that the difference is significant (p < 0.01).

[0091] The significant difference in fluorescence intensity between the NT-proBNP group and the control group indicates that the detection system produced a more significant response to the target analyte and had higher signal discrimination. These results demonstrate that the specific aptamer used in this embodiment can preferentially recognize NT-proBNP and effectively regulate the cleavage activity of the CRISPR / Cas12a system, thereby generating a fluorescence response signal significantly different from other proteins.

[0092] Therefore, the specific aptamer / CRISPR / Cas12a detection system constructed in this embodiment has good specific recognition ability and anti-interference ability for NT-proBNP, and can effectively distinguish NT-proBNP from cardiovascular-related markers such as CK-MB, HFABP, cTnI and BNP.

[0093] Example 5: This example explores the detection range of NT-proBNP concentration using lateral chromatography test strips and provides a method for detecting NT-proBNP concentration based on lateral chromatography test strips. The reaction buffer used in this example is the same as in Example 1.

[0094] The method in this embodiment includes the following steps: Step 1: Specific recognition response.

[0095] Prepare 5 mixed solutions of NT-proBNP and specific aptamers.

[0096] 60 μL of NT-proBNP working solutions with concentrations of approximately 1.08 pg / mL, 5.42 pg / mL, 54.17 pg / mL, 541.67 pg / mL, and 1083.33 pg / mL were taken, respectively. Then, 1 μL of a 6.5 μM specific aptamer solution was added to each NT-proBNP working solution, and the mixtures were thoroughly mixed to obtain five 61 μL mixed solutions of NT-proBNP and specific aptamers. The NT-proBNP working solution was prepared by resolving NT-proBNP in reaction buffer, and the specific aptamer solution was prepared by resolving the specific aptamer in reaction buffer. The sequence of the specific aptamer is: 5'-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3'.

[0097] Step 2: CRISPR / Cas12a signal amplification response.

[0098] Five Cas12a / crRNA mixtures were prepared, each with a volume of 2 μL. The crRNA concentration was 3.25 μM, and the Cas12a protein concentration was 6.5 μM. The Cas12a / crRNA mixtures were prepared using reaction buffer. The crRNA sequence was: 5'-UAAUUUCUACUAAGUGUAGAUCCGGUCUACGGUGGACAGUUUCCA-3'.

[0099] Add 1 μL of RNase inhibitor with an enzyme activity of 40 U / μL to each Cas12a / crRNA mixture and incubate at 37 °C for 15 min to obtain 5 incubated Cas12a / crRNA mixtures.

[0100] Add 3 μL of the incubated Cas12a / crRNA mixture and 1 μL of a 26 μM dual-labeled DNA reporter probe solution to each of the five mixtures obtained in step 1, forming five reaction systems, each with a volume of 65 μL. The sequence of the dual-labeled DNA reporter probe is: 5'-FAM-TTTTTTTTAAATTTTTTTTT-Biotin-3'. The dual-labeled DNA reporter probe solution was prepared by mixing the dual-labeled DNA reporter probe with the reaction buffer.

[0101] The five reaction systems were mixed thoroughly to allow the components in each system to react completely, resulting in five reaction solutions.

[0102] Step 3: Signal Measurement Prepare five lateral chromatography test strips and a handheld analyzer. Each lateral chromatography test strip includes a conjugate pad, a control line (C line), and a test line (T line). The conjugate pad is immobilized with colloidal gold-labeled anti-FITC / FAM antibody, the control line is coated with streptavidin, and the test line is coated with a secondary antibody against the anti-FITC / FAM antibody. The handheld analyzer includes an optical sensing module and a data processing module. The optical sensing module scans the T and C lines of the lateral chromatography test strip and reads their signal intensities. The data processing module pre-stores an NT-proBNP concentration standard curve and calculates the signal intensity ratio of the C line to the T line, i.e., the C / T ratio. Based on each C / T ratio and the logarithm of the final NT-proBNP concentration in the five reaction systems, an NT-proBNP concentration standard curve is constructed. Both the optical sensing module and the data processing module utilize mature technologies in their respective fields.

[0103] Immerse each of the five lateral chromatography test strips in one of the five reaction solutions, and let them stand until the T and C lines of each lateral chromatography test strip show stable color development and no longer change.

[0104] The signal intensities of the T and C lines of each lateral chromatography test strip were read using a handheld detector. The signal intensity ratio of the C line to the T line, i.e., the C / T ratio, was calculated. Based on each C / T ratio and the logarithm of the final NT-proBNP concentration in the five reaction systems, a standard curve for NT-proBNP concentration was obtained. Specific detection results are shown below. Figure 6 As shown.

[0105] It should be noted that in practical applications, the handheld detector pre-calibrates the NT-proBNP concentration standard curve through experiments and stores it in the data processing module. After the optical sensing module scans the T and C lines of the lateral chromatography test strip and reads the signal intensity of the T and C lines, the data processing module calculates the C / T ratio. Substituting this C / T ratio into the NT-proBNP concentration standard curve, the logarithm of the final NT-proBNP concentration can be obtained, which is then converted to obtain the final NT-proBNP concentration, i.e., the NT-proBNP concentration to be measured.

[0106] Depend on Figure 6 The results showed that the C-line of the lateral chromatography strip became increasingly darker with increasing NT-proBNP concentration. The C / T value was linearly correlated with the logarithm of the NT-proBNP concentration in the range of 1 to 1000 pg / mL. The linear regression equation was y = 0.1971x + 0.233 (R²). 2 =0.9556), where the dependent variable y represents the signal intensity ratio (C / T ratio) of the control line and the detection line on the lateral chromatography test strip, and the independent variable x represents the commonly used logarithmic value lg (C0.9556) of the NT-proBNP concentration in the 5 reaction systems. NT-proBNP (Concentration units are in pg / mL). The reaction group with an NT-proBNP concentration of 0 pg / mL was used as a blank control group. Based on the standard deviation of the C / T ratio obtained from repeated tests in the blank control group, the detection limit was determined using the 3σ principle. Combined with the above linear regression equation, the corresponding NT-proBNP concentration was calculated, resulting in an estimated detection limit of 536 fg / mL for NT-proBNP in this detection system.

[0107] Example 6: This example provides a urine NT-proBNP concentration detection kit based on aptamer-mediated CRISPR / Cas12a signal transduction. The kit includes: The specific aptamer has an NT-proBNP binding region that can specifically bind to NT-proBNP and a Cas12a activation region that can be recognized by crRNA; the sequence of the specific aptamer is: 5'-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3'. CRISPR reaction components include Cas12a protein, crRNA, and RNase inhibitors; the crRNA contains a guide sequence that can recognize the Cas12a activation region in a specific aptamer, and its sequence is: 5'-UAAUUUCUACUAAGUGUAGAUCCGGUCUACGGUGGACAGUUUCCA-3'. The dual-labeled DNA reporter probe has the following sequence: 5'-FAM-TTTTTTTTAAATTTTTTTTT-Biotin-3'; The reaction buffer consisted of 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2 and 100 μg / mL recombinant albumin; And lateral chromatography test strips, including a conjugate pad, a control line, and a test line; the conjugate pad is immobilized with colloidal gold-labeled anti-FITC / FAM antibody, the control line is coated with streptavidin, and the test line is coated with a secondary antibody against anti-FITC / FAM antibody.

[0108] The kit in this embodiment also includes reaction tubes; each reaction tube includes a tube body and a cap for sealing the tube body; the specific aptamer is pre-loaded in the tube body in lyophilized powder form, and the CRISPR reaction components and the dual-labeled DNA reporter probe are both pre-loaded in the cap body in lyophilized powder form; wherein, the cap is a rotary cap, rotating the rotary cap releases the CRISPR reaction components and the dual-labeled DNA reporter probe, causing them to fall into the tube body. The reaction buffer is individually packaged.

[0109] The kit in this embodiment contains, on a single-reaction basis, 6.5 pmol of specific aptamer, 26 pmol of double-labeled DNA reporter probe, 6.5 pmol of crRNA, 13 pmol of Cas12a protein, and 40 U of RNase inhibitor based on the amount of enzyme activity added before lyophilization. Each kit includes 58 μL of reaction buffer for processing 2 μL of urine sample. Urine samples were obtained from 8 volunteers as test samples, resulting in 8 urine collections. Among them, 4 volunteers were heart failure patients (heart failure patient group), and the other 4 volunteers were healthy individuals (normal control group).

[0110] Eight kits from this embodiment were prepared, and the NT-proBNP concentration of each urine sample was detected at room temperature. Figure 1 A flowchart illustrating the use of the kit described in this embodiment and the detection of NT-proBNP in urine with a handheld testing device is shown. Figure 1 In this context, Biotin-DNA-FAM represents a dual-labeled DNA reporter probe. The handheld detector includes an optical sensing module and a data processing module. The optical sensing module scans the T and C lines of the lateral chromatography test strip and reads their signal intensities. The data processing module includes a pre-established NT-proBNP concentration standard curve, which is used to calculate the signal intensity ratio of the C line to the T line, i.e., the C / T ratio. This value is then substituted into the NT-proBNP concentration standard curve to obtain the logarithm of the NT-proBNP concentration, and thus the NT-proBNP concentration. The NT-proBNP concentration standard curve was established using the same method as in Example 5.

[0111] The specific testing process for testing a sample of urine using one kit from this embodiment is as follows: Step 1: Specific recognition response.

[0112] Both the urine sample and the reaction buffer are added to the tube. The specific aptamer is reconstituted by the reaction buffer and is in a free state. The urine sample is diluted by the reaction buffer. At this time, part of the specific aptamer specifically binds to NT-proBNP in the urine sample to form an aptamer-NT-proBNP complex, while the other part is in a free state. Step 2: CRISPR / Cas12a signal amplification response.

[0113] Rotate the cap to release the CRISPR reaction components and the dual-labeled DNA reporter probe into the tube. Let it stand for 15 minutes. The crRNA and Cas12a protein form the Cas12a-crRNA complex. The free-state specific aptamer recognizes the Cas12a-crRNA complex and activates a portion of the Cas12a-crRNA complex. The activated Cas12a-crRNA complex cleaves the dual-labeled DNA reporter probe, resulting in the cleavage of one part of the dual-labeled DNA reporter probe while the other part remains intact, thus obtaining the reaction solution.

[0114] Step 3: Signal measurement.

[0115] Immerse the lateral chromatography test strip in the reaction solution inside the tube until the T and C lines of the lateral chromatography test strip show stable color development and no longer change.

[0116] After testing eight urine samples using the kit described in this embodiment, eight colorimetrically stable lateral chromatography test strips were obtained.

[0117] At this point, a handheld detector is used to read the signal intensity of the T line and C line of the eight colorimetrically stable lateral chromatography test strips, and the signal intensity ratio of the C line to the T line (C / T ratio) is calculated. The value of the NT-proBNP concentration is then substituted into the NT-proBNP concentration standard curve to calculate the logarithmic value of the NT-proBNP concentration, and finally converted into the NT-proBNP concentration output.

[0118] The display results of each lateral chromatography test strip in this embodiment were quantified, and the T-line and C-line signal intensities of each urine sample corresponding to the lateral chromatography test strip were obtained as shown in Table 1: Table 1: Signal intensity of T and C lines on lateral chromatography test strips corresponding to urine samples

[0119] Analysis of the data in Table 1 shows that the C / T ratio in the heart failure patient group was significantly higher than that in the normal control group. This indicates that NT-proBNP in the urine of heart failure patients binds to specific aptamers, the number of free specific aptamers decreases, the activation of the Cas12a-crRNA complex decreases, the degree of cleavage of the double-labeled DNA reporter probe decreases, and the number of uncleaved, intact double-labeled DNA reporter probes increases. Therefore, the C line is enhanced and the C / T ratio is increased.

[0120] As can be seen from the above detection data, the present invention can distinguish the NT-proBNP concentration between heart failure patients and normal control groups by detecting the degree of cleavage of the dual-labeled DNA reporter probe.

[0121] In practical use, the kit of this invention pre-fixes and stores the specific aptamer dosage, CRISPR reaction component dosage, dual-labeled DNA reporter probe dosage, and reaction buffer dosage. The urine sample is calibrated with an appropriate volume. After preparing the urine sample according to the appropriate volume, the user can perform the detection operation according to the detection process in Example 6. For the handheld detector, its optical sensing module and data processing module both adopt mature technologies in the field and can be integrated into a single housing. The housing is equipped with a display screen connected to the data processing module. The data processing module displays the obtained NT-proBNP concentration on the display screen, thereby achieving quantitative reading of the NT-proBNP concentration.

Claims

1. An aptamer-based urine NT-proBNP concentration detection kit for mediating CRISPR / Cas12a signal conversion, characterized in that, include: The specific aptamer has an NT-proBNP binding region that can specifically bind to NT-proBNP and a Cas12a activation region that can be recognized by crRNA. CRISPR reaction components include Cas12a protein, crRNA, and RNase inhibitor; the crRNA contains a guide sequence that matches the Cas12a activation region in the specific aptamer and is capable of forming a Cas12a-crRNA complex with the Cas12a protein. A dual-labeled DNA reporter probe, with one end labeled with FAM and the other end labeled with Biotin, can be trans-cleaved by the activated Cas12a-crRNA complex. The reaction buffer is used to reconstitute the specific aptamer, the CRISPR reaction components and the dual-labeled DNA reporter probe, dilute the urine sample and provide the reaction conditions required for the aptamer-NT-proBNP binding reaction and the Cas12a-crRNA complex cleavage reaction. And a lateral chromatography test strip, including a conjugate pad, a control line and a test line; the conjugate pad is immobilized with colloidal gold-labeled anti-FITC / FAM antibody, the control line is coated with streptavidin, and the test line is coated with a secondary antibody against the anti-FITC / FAM antibody; The sequence of the specific aptamer is: 5'-GGCAGGAAGACAAACAGGTCGTAGTGGAAACTGTCCACCGTAGACCGGTTATCTAGTGGTCTGTGGTGCTGT-3'; the sequence of the crRNA is: 5'-UAAUUUCUACUAAGUGUAGAUCCGGUCUACGGUGGACAGUUUCCA-3'; the sequence of the dual-labeled DNA reporter probe is: 5'-FAM-TTTTTTTTAAATTTTTTTTT-Biotin-3'.

2. The reagent kit according to claim 1, characterized in that, It also includes a reaction tube; the reaction tube includes a tube body and a cap for sealing the tube body; the specific aptamer is pre-loaded in the tube body in the form of lyophilized powder, and the CRISPR reaction components and the dual-labeled DNA reporter probe are both pre-loaded in the cap body in the form of lyophilized powder; the reaction buffer is individually packaged.

3. The reagent kit according to claim 2, characterized in that, The cap is a rotating cap. Rotating the cap releases the CRISPR reaction components and the dual-labeled DNA reporter probe, causing them to fall into the tube and mix with the reconstituted specific aptamer.

4. The reagent kit according to claim 1, characterized in that, Based on a single reaction, the amount of the specific aptamer is 1.5–15 pmol, the amount of the crRNA is 3.25–13 pmol, the molar ratio of the Cas12a protein to the crRNA is 1:1–4:1, and the amount of the RNase inhibitor added is 20–80 U.

5. The reagent kit according to claim 4, characterized in that, The molar ratio of the specific aptamer, the dual-labeled DNA reporter probe, the Cas12a protein, and the crRNA is 1:4:2:

1.

6. The reagent kit according to claim 5, characterized in that, Based on a single reaction, the amount of the specific aptamer is 6.5 pmol, the amount of enzyme activity of the RNase inhibitor added is 40 U, ​​the volume of the reaction buffer is 58 μL, and the volume ratio of the reaction buffer to the urine sample to be tested is 29:

1.

7. The kit according to claim 1, characterized in that, It also includes a handheld detector, which is used to read the signal intensity of the test line and the control line of the lateral chromatography test strip, calculate the signal intensity ratio of the control line to the test line of the lateral chromatography test strip, and obtain the corresponding NT-proBNP concentration according to the NT-proBNP concentration standard curve.

8. The reagent kit according to claim 7, characterized in that, The handheld detector includes: An optical sensing module is used to scan the control line and the detection line of the lateral chromatography test strip and to quantify the signal intensity of the control line and the detection line of the lateral chromatography test strip. The data processing module is pre-stored with an NT-proBNP concentration standard curve, which is used to calculate the signal intensity ratio between the control line and the detection line of the lateral chromatography test strip, and substitute the signal intensity ratio into the NT-proBNP concentration standard curve to obtain the corresponding NT-proBNP concentration.

9. The use of the kit according to any one of claims 1 to 8 in the preparation of a heart failure assessment product.

Citation Information

Patent Citations

  • Lateral chromatography paper and sensor for detecting heart failure biomarker NT-proBNP

    CN119534838A

  • Test kit for detecting concentration of cardiovascular disease-related biomarker and concentration detection method for detecting concentration of cardiovascular disease-related biomarker

    US20200283847A1